Vivani Medical Inc.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatid… Read more
Vivani Medical Inc. (VANI) - Net Assets
Latest net assets as of September 2025: $1.31 Million USD
Based on the latest financial reports, Vivani Medical Inc. (VANI) has net assets worth $1.31 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.05 Million) and total liabilities ($23.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.31 Million |
| % of Total Assets | 5.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | 803.08% |
| 10-Year Change | -13.11% |
| Growth Volatility | 517.66 |
Vivani Medical Inc. - Net Assets Trend (2012–2024)
This chart illustrates how Vivani Medical Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vivani Medical Inc. (2012–2024)
The table below shows the annual net assets of Vivani Medical Inc. from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $17.61 Million | -15.18% |
| 2023-12-31 | $20.76 Million | -53.14% |
| 2022-12-31 | $44.31 Million | +1697.48% |
| 2021-12-31 | $2.46 Million | +26.41% |
| 2020-12-31 | $1.95 Million | -73.20% |
| 2019-12-31 | $7.28 Million | +135.89% |
| 2018-12-31 | $3.08 Million | -60.87% |
| 2017-12-31 | $7.88 Million | -29.31% |
| 2016-12-31 | $11.15 Million | -44.99% |
| 2015-12-31 | $20.27 Million | -41.45% |
| 2014-12-31 | $34.62 Million | +475.43% |
| 2013-12-31 | $-9.22 Million | -202.94% |
| 2012-12-31 | $-3.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vivani Medical Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2743020400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.03% |
| Other Comprehensive Income | $48.00K | 0.27% |
| Other Components | $139.48 Million | 792.05% |
| Total Equity | $17.61 Million | 100.00% |
Vivani Medical Inc. Competitors by Market Cap
The table below lists competitors of Vivani Medical Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NEOWIZ HOLDINGS Corporation
KQ:042420
|
$41.81 Million |
|
Lake Shore Bancorp Inc
NASDAQ:LSBK
|
$41.82 Million |
|
Sajodongaone Co Ltd
KO:008040
|
$41.84 Million |
|
Chi Sheng Chemical
TWO:4111
|
$41.85 Million |
|
Adler Group S.A
PINK:ADPPF
|
$41.80 Million |
|
Battalion Oil Corp
NYSE MKT:BATL
|
$41.80 Million |
|
Mono Next Public Company Limited
BK:MONO
|
$41.80 Million |
|
Kopla Co. Ltd
KQ:126600
|
$41.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vivani Medical Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 20,761,000 to 17,610,000, a change of -3,151,000 (-15.2%).
- Net loss of 23,486,000 reduced equity.
- New share issuances of 18,817,000 increased equity.
- Other comprehensive income decreased equity by 92,000.
- Other factors increased equity by 1,610,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-23.49 Million | -133.37% |
| Share Issuances | $18.82 Million | +106.85% |
| Other Comprehensive Income | $-92.00K | -0.52% |
| Other Changes | $1.61 Million | +9.14% |
| Total Change | $- | -15.18% |
Book Value vs Market Value Analysis
This analysis compares Vivani Medical Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.81x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.65 | $1.22 | x |
| 2013-12-31 | $-1.95 | $1.22 | x |
| 2014-12-31 | $10.14 | $1.22 | x |
| 2015-12-31 | $4.14 | $1.22 | x |
| 2016-12-31 | $2.01 | $1.22 | x |
| 2017-12-31 | $1.11 | $1.22 | x |
| 2018-12-31 | $0.36 | $1.22 | x |
| 2019-12-31 | $0.47 | $1.22 | x |
| 2020-12-31 | $0.07 | $1.22 | x |
| 2021-12-31 | $0.07 | $1.22 | x |
| 2022-12-31 | $1.16 | $1.22 | x |
| 2023-12-31 | $0.41 | $1.22 | x |
| 2024-12-31 | $0.32 | $1.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vivani Medical Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -133.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.36x
- Recent ROE (-133.37%) is above the historical average (-287.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -1190.67% | 0.17x | 0.00x | $-15.97 Million |
| 2013 | 0.00% | -1467.73% | 0.12x | 0.00x | $-22.05 Million |
| 2014 | -101.68% | -1035.99% | 0.08x | 1.24x | $-38.66 Million |
| 2015 | -98.77% | -223.66% | 0.32x | 1.39x | $-22.04 Million |
| 2016 | -297.57% | -832.60% | 0.24x | 1.51x | $-34.29 Million |
| 2017 | -361.79% | -358.06% | 0.55x | 1.84x | $-29.30 Million |
| 2018 | -1137.94% | -508.90% | 0.65x | 3.46x | $-35.40 Million |
| 2019 | -461.75% | -994.14% | 0.20x | 2.28x | $-34.32 Million |
| 2020 | -475.85% | -927900.00% | 0.00x | 2.68x | $-9.47 Million |
| 2021 | -518.17% | -4912692.31% | 0.00x | 2.21x | $-13.02 Million |
| 2022 | -31.35% | 0.00% | 0.00x | 1.15x | $-18.32 Million |
| 2023 | -123.56% | 0.00% | 0.00x | 2.21x | $-27.73 Million |
| 2024 | -133.37% | 0.00% | 0.00x | 2.36x | $-25.25 Million |
Industry Comparison
This section compares Vivani Medical Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vivani Medical Inc. (VANI) | $1.31 Million | 0.00% | 18.13x | $41.81 Million |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |